Cancer care continues to pose one of the most formidable public health challenges of the twenty-first century, as an increasingly disproportionate burden is borne by low- and middle-income countries (LMICs). The increasing epidemiology of malignancies in LMICs, delayed presentation, increasing morbidity from the disease, lack of ready access traditional and precision treatment with eventual poor outcomes are characteristics of cancer care in LMICs exposing the profound weaknesses and gaps in the health systems in these resource constrained settings regarding.
Current evidence as provided by recent estimates from the World Health Organization (WHO) and the
International Agency for Research on Cancer (IARC) suggest that the steepest proportional increases in cancer incidence and mortality are expected in lowerincome countries over the coming decades despite having the least capacity to respond effectively to the growing burden of disease.1
Furthermore, the substantial inequities between LMICs and High-income countries (HICs) in access to screening, diagnosis, treatment, palliative care for cancer care is attributed the lack of financial protection of
patients with cancer diagnosis.2 Thus, creating a widening gap between cancer outcomes in highincome countries and those in LMICs.